This is to notify the research community of the recently extended deadline for the Fiscal Year 2018 (FY18) funding opportunities for the Department of Defense (DOD) Kidney Cancer Research Program (KCRP) being managed by the office of Congressionally Directed Medical Research Programs (CDMRP).
On September 7th, the Harvard Medical Research Centers including Dana Farber, Beth Isreal, Brigham & Women's will once again hold their annual Kidney Cancer Symposium at the Newton Massachessetts Marriott. The Symposium is an all-day in-person and virtual event beginning at 8:00 a.m. and concluding at 3:30 pm.
KCCure hits goal of raising $50,000 in new kidney cancer research funding. Learn more about our Kidney Cancer Research Grant Program and our mission for find a cure for kidney cancer.
July 30, 2018 Washington, DC, – The Kidney Cancer Research Alliance(KCCure) responded to the Committee for Medicinal Products for Human Use (CHMP) recommendation against approval by the European Medicines Agency (EMA) of ipilimumab (Yervoy) combined with nivolumab (Opdivo) for the first line treatment of high and intermediate risk metastatic renal cell carcinoma (kidney cancer). The question of single-agent versus combination therapy is relevant in kidney cancer today and we agree with CHMP that additional data showing the superiority of adding ipilimumab to nivolumab would benefit the field and broaden our understanding of how these agents work in kidney cancer. However, we don’t believe this question alone is sufficient enough to justify denying kidney cancer patients access to a treatme...
During ASCO, new data was presented from the “CARMENA” trial showing that overall survival for metastatic patients was not improved by performing a nephrectomy (or removing the primary tumor). This is a controversial question and one that is being debated by many physicians. We want to include the patient voice in that debate. Please take a few minutes to fill out this brief survey to help us sharing the patient perspective at ASCO. As always, your personal data will not be sharing with anyone. Thank you for taking part!
For the second year in a row, KCCure represented kidney cancer patients at the annual meeting for the American Urological Association. This year, KCCure was instrumental in planning for the meeting by serving on the AUA Steering Committee for Patient Advocacy Efforts.
Kidney Cancer Research Alliance (KCCure) President Dena Battle has been elected to represent patients on the National Cancer Institute's Genitourinary Steering Committee(GUSC). The primary focus of the committee is to address design prioritization and evaluation of concepts for phase 2 and 3 clinical trials in GU cancers. Her term is effective May 25, 2018 and will last through May 2021.
“Today’s decision by the FDA is a game-changer for patients and physicians managing advanced kidney cancer,” said Hans Hammers M.D., Ph.D., KCCure co-founder and senior co-author of the clinical study for the combination.